The Indian pharma and healthcare industry is looking to build on the experience of the last two years, strengthen the partnership with the government, and maintain the momentum in 2022, after demonstrating its prowess to the world during the difficult times of the pandemic by supplying 60% of global COVID-19 vaccine requirements.
K G Ananthakrishnan, Director-General of the Organisation of Pharmaceutical Producers of India (OPPI), said it is critical for the industry to maintain momentum toward the accomplishments made during the epidemic, which will enable it to establish a position in the global pharma value chain.
